retatrutide peptide source 🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Retatrutide Research Peptide Canada |

Eli Lilly initiated the TRIUMPH Phase 3 program in late 2024 , with interim data expected to support a 2027 FDA submission and peak GLP-1 market sales projections of USD 12 to USD 18 billion

[6] People with certain conditions such as significant lipodystrophy or a history of skin reactions to injectable medications may require additional clinical input before beginning treatment

The clinical-trial figures cited below are reported for context only

"Launching the oral formulations first, it allowed us to build out the platform to look at how we manage our weight loss patients

Cardiometabolic Research Beyond weight reduction, retatrutide's glucagon receptor component has attracted research interest for its cardiovascular effects

Similarly, cutting or modifying patches to adjust dosing is dangerous and should never be attempted, as this can cause rapid, uncontrolled drug release and potential overdose